Non-Small Cell Lung Cancer Market
Report ID: SQMIG25K2005
Report ID:
SQMIG25K2005 |
Region:
Global |
Published Date: February, 2024
Pages:
165
|Tables:
36
|Figures:
74
Global Non-Small Cell Lung Cancer Market size was valued at USD 23.66 billion in 2019 and is poised to grow from USD 26.94 billion in 2023 to USD 76.33 billion by 2031, growing at a CAGR of 13.9% in the forecast period (2024-2031).
The introduction of immune checkpoint inhibitors (ICIs) into the first-line context is one of the main drivers influencing market revenue growth. Eighty to eighty-five percent of lung cancer occurrences worldwide are non-small cell lung cancer, and because of this high percentage, the majority of market leaders are concentrating on constantly developing new therapies and enhancing the effectiveness of already-available medications. The market expansion is also attributable to lung cancer's notoriety as one of the most prevalent malignancies that causes a sizable number of fatalities worldwide. Increased non-small cell lung cancer diagnoses and greater public knowledge of the condition in developed and developing nations both contribute to the growth of the non-small cell lung cancer market. The inclusion of non-small cell cancer medicines in the pipelines of key market participants, together with increased investment in research and development activities by top businesses, is boosting the global market's growth.
To get more reports on the above market click here to Buy The Report
The global non-small cell lung cancer market is segmented based on therapy, region. Based on therapy it is categorized into targeted therapy, chemotherapy, and immunotherapy. Based on region it is categorized into: North America, Europe, Asia-Pacific, South America, and MEA.
Non-Small Cell Lung Cancer Market Analysis by Pest Type
The targeted therapy segment dominated the global non-small cell lung cancer Market in the year 2021 with more than 51% of market share. A type of treatment called targeted therapy employs medications or other chemicals to target particular cancer cells. Compared to chemotherapy or radiation therapy, these treatments typically don't kill normal cells as much.
To get detailed analysis on other segments, Request For Free Sample Report
By region, the non-small cell lung cancer market is spread across North America, Europe, Asia-Pacific, and LAMEA. North America earned USD 5.6 billion in revenue from the non-small cell lung cancer therapies market in 2021, and it is projected that over the forecast period, it would hold a leading position of this market. The fact that between 80% and 85% of all occurrences of lung cancer are NSCLC is the main reason for the market's considerable and rapid expansion.
The acceptance of non-small cell lung cancer therapies is anticipated to increase with the rise in lung cancer risk factors, such as the percentage of smokers in the general population and exposure to toxins like asbestos and air pollution. Along with the other crucial medicines of chemotherapy and targeted therapy, the use of sophisticated immunotherapies is expanding in wealthy nations.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Non-Small Cell Lung Cancer Market Driver
Non-Small Cell Lung Cancer Market Restraint
Request Free Customization of this report to help us to meet your business objectives.
Top Players in the Global Non-Small Cell Lung Cancer Market
Non-Small Cell Lung Cancer Market Recent Developments
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates and Analyses the Data collected by means of Primary Exploratory Research backed by the robust Secondary Desk research.
According to our analysis, by therapy, the targeted therapy segment has the largest share of the market. Region-wise, the North America region accounted highest market share with more than 80% of total market revenue.
Report Metric | Details |
---|---|
Market size value in 2023 | USD 23.66 billion |
Market size value in 2031 | USD 76.33 billion |
Growth Rate | 13.9% |
Forecast period | 2024-2031 |
Forecast Unit (Value) | USD Billion |
Segments covered |
|
Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
Companies covered |
|
Customization scope | Free report customization with purchase. Customization includes:-
|
Historical Year | 2019 |
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
For the Non-Small Cell Lung Cancer Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Non-Small Cell Lung Cancer Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Non-Small Cell Lung Cancer Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Non-Small Cell Lung Cancer Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Non-Small Cell Lung Cancer Market size was valued at USD 23.66 billion in 2019 and is poised to grow from USD 26.94 billion in 2023 to USD 76.33 billion by 2031, growing at a CAGR of 13.9% in the forecast period (2024-2031).
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQMIG25K2005
sales@skyquestt.com
USA +1 351-333-4748